PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2019
• Market size and forecast 2019-2024
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Hemophilia A – Market size and forecast 2019-2024
• Hemophilia B – Market size and forecast 2019-2024
• Von Willebrand disease – Market size and forecast 2019-2024
• Other disorders – Market size and forecast 2019-2024
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2019-2024
• Europe – Market size and forecast 2019-2024
• Asia – Market size and forecast 2019-2024
• ROW – Market size and forecast 2019-2024
• Key leading countries
• Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• R&D of novel therapies
• Emergence of gene therapy
• Advent of bispecific antibodies
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Baxter International Inc.
• Bayer AG
• CSL Ltd.
• F. Hoffmann-La Roche Ltd.
• Grifols SA
• Novo Nordisk AS
• Octapharma AG
• Pfizer Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2019
Exhibit 08: Global market: Size and forecast 2019-2024 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2020-2024 (%)
Exhibit 10: Five forces analysis 2019
Exhibit 11: Five forces analysis 2024
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2019
Exhibit 18: Late-stage pipeline
Exhibit 19: Type – Market share 2019-2024 (%)
Exhibit 20: Comparison by type
Exhibit 21: Hemophilia A – Market size and forecast 2019-2024 ($ millions)
Exhibit 22: Hemophilia A – Year-over-year growth 2020-2024 (%)
Exhibit 23: Hemophilia B – Market size and forecast 2019-2024 ($ millions)
Exhibit 24: Hemophilia B – Year-over-year growth 2020-2024 (%)
Exhibit 25: Von Willebrand disease – Market size and forecast 2019-2024 ($ millions)
Exhibit 26: Von Willebrand disease – Year-over-year growth 2020-2024 (%)
Exhibit 27: Other disorders – Market size and forecast 2019-2024 ($ millions)
Exhibit 28: Other disorders – Year-over-year growth 2020-2024 (%)
Exhibit 29: Market opportunity by type
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2019-2024 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America – Market size and forecast 2019-2024 ($ millions)
Exhibit 34: North America – Year-over-year growth 2020-2024 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe – Market size and forecast 2019-2024 ($ millions)
Exhibit 37: Europe – Year-over-year growth 2020-2024 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia – Market size and forecast 2019-2024 ($ millions)
Exhibit 40: Asia – Year-over-year growth 2020-2024 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW – Market size and forecast 2019-2024 ($ millions)
Exhibit 43: ROW – Year-over-year growth 2020-2024 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Vendor landscape
Exhibit 49: Landscape disruption
Exhibit 50: Vendors covered
Exhibit 51: Vendor classification
Exhibit 52: Market positioning of vendors
Exhibit 53: Baxter International Inc. – Vendor overview
Exhibit 54: Baxter International Inc. – Business segments
Exhibit 55: Baxter International Inc. – Organizational developments
Exhibit 56: Baxter International Inc. – Geographic focus
Exhibit 57: Baxter International Inc. – Segment focus
Exhibit 58: Baxter International Inc. – Key offerings
Exhibit 59: Baxter International Inc. – Key customers
Exhibit 60: Bayer AG – Vendor overview
Exhibit 61: Bayer AG – Business segments
Exhibit 62: Bayer AG – Organizational developments
Exhibit 63: Bayer AG – Geographic focus
Exhibit 64: Bayer AG – Segment focus
Exhibit 65: Bayer AG – Key offerings
Exhibit 66: Bayer AG – Key customers
Exhibit 67: CSL Ltd. – Vendor overview
Exhibit 68: CSL Ltd. – Business segments
Exhibit 69: CSL Ltd. – Organizational developments
Exhibit 70: CSL Ltd. – Geographic focus
Exhibit 71: CSL Ltd. – Segment focus
Exhibit 72: CSL Ltd. – Key offerings
Exhibit 73: CSL Ltd. – Key customers
Exhibit 74: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 75: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 76: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 77: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 78: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 79: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 80: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 81: Grifols SA – Vendor overview
Exhibit 82: Grifols SA – Business segments
Exhibit 83: Grifols SA – Organizational developments
Exhibit 84: Grifols SA – Geographic focus
Exhibit 85: Grifols SA – Segment focus
Exhibit 86: Grifols SA – Key offerings
Exhibit 87: Grifols SA – Key customers
Exhibit 88: Novo Nordisk AS – Vendor overview
Exhibit 89: Novo Nordisk AS – Business segments
Exhibit 90: Novo Nordisk AS – Organizational developments
Exhibit 91: Novo Nordisk AS – Geographic focus
Exhibit 92: Novo Nordisk AS – Segment focus
Exhibit 93: Novo Nordisk AS – Key offerings
Exhibit 94: Novo Nordisk AS – Key customers
Exhibit 95: Octapharma AG – Vendor overview
Exhibit 96: Octapharma AG – Organizational developments
Exhibit 97: Octapharma AG – Key offerings
Exhibit 98: Octapharma AG – Key customers
Exhibit 99: Pfizer Inc. – Vendor overview
Exhibit 100: Pfizer Inc. – Business segments
Exhibit 101: Pfizer Inc. – Organizational developments
Exhibit 102: Pfizer Inc. – Geographic focus
Exhibit 103: Pfizer Inc. – Segment focus
Exhibit 104: Pfizer Inc. – Key offerings
Exhibit 105: Pfizer Inc. – Key customers
Exhibit 106: Sanofi – Vendor overview
Exhibit 107: Sanofi – Business segments
Exhibit 108: Sanofi – Organizational developments
Exhibit 109: Sanofi – Geographic focus
Exhibit 110: Sanofi – Segment focus
Exhibit 111: Sanofi – Key offerings
Exhibit 112: Sanofi – Key customers
Exhibit 113: Takeda Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 114: Takeda Pharmaceutical Co. Ltd. – Business segments
Exhibit 115: Takeda Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 116: Takeda Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 117: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibit 118: Takeda Pharmaceutical Co. Ltd. – Key customers
Exhibit 119: Validation techniques employed for market sizing
Exhibit 120: Definition of market positioning of vendors
【掲載企業】
Baxter International Inc., Bayer AG, CSL Ltd., F. Hoffmann-La Roche Ltd., Grifols SA, Novo Nordisk AS, Octapharma AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Co. Ltd.
【免責事項】
https://www.marketreport.jp/reports-disclaimer